ProCE Banner Series

Immune Checkpoint Inhibitor-Based Combinations for Patients With NSCLC and Acquired Resistance to Immunotherapy

Join us online for this interactive roundtable webinar featuring Karen L. Reckamp, MD, and Christine Bestvina, MD, live from the IASLC 2023 North America Conference on Lung Cancer discussing novel approaches to extend the benefits of immunotherapy after disease progression in advanced NSCLC. Register now!

To Register:  Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AMA
Credits Available

1.0

Who Should Attend

This program is intended for medical oncologists and other healthcare professionals who care for patients with lung cancer.

All Events

Immune Checkpoint Inhibitor-Based Combinations for Patients With NSCLC and Acquired Resistance to Immunotherapy

Past Events

December

01

2023

8:00 AM - 9:00 AM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Christine M. Bestvina, MD

Assistant Professor
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois

ProCE Banner Faculty
Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Professor, Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, California

Topics

  • Welcome and Introduction
  • Medical Need for New Therapeutic Options in Advanced NSCLC With Resistance to IO
    • Role of IO in the Treatment of Advanced NSCLC
    • Acquired resistance to IO
      • Definition
      • Current Standard of Care
      • Impact of IO in Setting of Early-Stage Disease
  • Combination IO/Anti-VEGF(R) Therapy in NSCLC With Resistance to IO
    • Rationale
    • Available Efficacy and Safety Data
  • Clinical Trials of Combination IO/Anti-VEGF(R) Therapy in NSCLC With Resistance to IO
    • Adverse Events with IO and Anti-VEGF(R) Therapy and Their Optimal Management
  • Role of Antibody–Drug Conjugate Therapy After IO in Advanced NSCLC
  • Final Panel Discussion and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Target Audience
This program is intended for medical oncologists and other healthcare professionals who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the clinical rationale for therapeutic strategies that extend the benefits of immune checkpoint inhibitor therapy after progression 
  • Apply available and emerging clinical evidence on IO/anti-VEGF combination therapies to practice for patients with NSCLC who have acquired resistance to ICI therapy 
  • Plan therapeutic strategies for patients with advanced or metastatic NSCLC and disease progression on or after ICI-based therapy
  • Manage AEs associated with IO/anti-VEGF combination therapies leveraging the available clinical data and clinical tools

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Lilly.